Sonya Addison, MD
Endocrinology, Diabetes & Metabolism · Columbia, MONPI 1215199369
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $15,963 of the $25,281 with a category attached, or 63.1%. Medtronic accounts for 78.5% of it on its own, with 37 other manufacturers making up the rest. Reporting peaked in 2021 at $8,960 and has fallen 79.9% since, to $1,798 in 2025.
Across 350 payments — averaging $72.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$20K
- Novo Nordisk$864
- Dexcom, Inc.$859
- Amgen$388
- AbbVie$373
- Corcept Therapeutics$353
- plus $3K from 32 others
What the payments were for
- Speaking & faculty fees$15,96363%
- Travel & lodging$2,0218%
- Food & beverage$7,25029%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 59 | $19,852 |
| Novo Nordisk | 65 | $864 |
| Dexcom, Inc. | 46 | $859 |
| Amgen | 22 | $388 |
| AbbVie | 19 | $373 |
| Corcept Therapeutics | 17 | $353 |
| Sanofi-aventis U.S. LLC | 10 | $302 |
| Lilly USA, LLC | 16 | $264 |
| Recordati_rare_diseases_inc. | 8 | $234 |
| Abbott | 13 | $218 |
| AstraZeneca(2 entities) | 8 | $216 |
| Merck | 9 | $160 |
| Xeris Pharmaceuticals, Inc. | 7 | $142 |
| Averitas Pharma Inc. | 4 | $135 |
| Boehringer Ingelheim | 6 | $112 |
| Cequr Corporation | 2 | $77 |
| Viiv Healthcare Company | 3 | $68 |
| Paratek Pharmaceuticals, Inc. | 4 | $66 |
| Bayer | 3 | $63 |
| Radius Health, Inc. | 3 | $50 |
| Sequel Med Tech, LLC | 2 | $49 |
| Ascensia Diabetes Care US Inc. | 2 | $45 |
| Tandem Diabetes Care, Inc. | 4 | $43 |
| Insulet Corporation | 2 | $42 |
| La Jolla Pharmaceutical Company | 2 | $35 |
| BETA Bionics, Inc. | 1 | $31 |
| Ferring Pharmaceuticals Inc. | 1 | $29 |
| Amneal Pharmaceuticals LLC | 2 | $27 |
| Pfizer | 1 | $26 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| Novartis | 1 | $22 |
| Mannkind Corporation | 1 | $21 |
| Amphastar Pharmaceuticals, Inc. | 1 | $20 |
| Chiesi USA, Inc. | 1 | $20 |
| GSK | 1 | $14 |
| Sun Pharmaceutical Industries Inc. | 1 | $13 |
| Organogenesis Inc. | 1 | $13 |
| Ultragenyx Pharmaceutical Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 770G$4,774
- Guardian Connect$3,994
- InPen$3,446
- Minimed 670G System$3,250
- Minimed 770G System$2,250
- MINIMED 780G$434
- INPEN SMART INSULIN DELIVERY SYSTEM$131
- VANTA ADAPTIVESTIM$124
- Minimed 530G$122
- SOLIQUA 100/33$103
How this compares
$25,281 in reported general payments places this provider in the 85th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
See all endocrinology, diabetes & metabolism providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 547 | $700,684 |
| MounjaroTirzepatide | 293 | $386,717 |
| JardianceEmpagliflozin | 376 | $351,471 |
| FarxigaDapagliflozin Propanediol | 138 | $133,450 |
| Tresiba Flextouch U-100Insulin Degludec | 115 | $94,588 |
| TrulicityDulaglutide | 62 | $72,087 |
| Tresiba Flextouch U-200Insulin Degludec | 43 | $68,889 |
| JanuviaSitagliptin Phosphate | 53 | $59,513 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 32 | $59,361 |
| Humalog Kwikpen U-200Insulin Lispro | 21 | $44,095 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 221 | $42,597 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 33 | $42,237 |
| Humalog Kwikpen U-100Insulin Lispro | 64 | $40,736 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $37,751 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 35 | $32,773 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Rybelsus, Novolog | $864 | $756,828610 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $264 | $484,134462 claims |
| Boehringer IngelheimJardiance, Synjardy | $112 | $372,686398 claims |
| AstraZenecaFarxiga | $216 | $133,450138 claims |
| MerckJanuvia | $160 | $59,51353 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $27 | $6,919671 claims |
| AbbVieSynthroid | $373 | $4,48376 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
Other endocrinology, diabetes & metabolism in Columbia
- Michael GardnerColumbia$40K
- Sean HamlettColumbia$6K
- Ralph DudaSpringfield$644K
- Karen Chang-ChenChesterfield$640K
- Alan RaubaJefferson City$594K
- Jerome ThurmanSaint Charles$312K
- Janet McGillSaint Louis$212K
- Megan WoodSt. Louis$207K
- Ralph OiknineChesterfield$144K
- Jonben SvobodaSpringfield$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.